<DOC>
	<DOCNO>NCT00921661</DOCNO>
	<brief_summary>The primary objective determine dose aflibercept studied combination irinotecan/5-fluorouracil/isovorin ( FOLFIRI ) Japanese patient metastatic colorectal cancer . Secondary objective study assess safety profile aflibercept , determine pharmacokinetics aflibercept , make preliminary assessment antitumor effect .</brief_summary>
	<brief_title>Study Intravenous Aflibercept Combination With FOLFIRI Japanese Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients histologically cytologically proven malignant tumor colon rectum metastatic inoperable . Patients must receive least one prior line treatment standard care , fail treatment , eligible standard care safety reason . Treatment chemotherapy , hormone therapy , radiotherapy , surgery , blood product , investigational agent within 28 day . ECOG Performance Status &gt; 1 Anticipated need major surgical procedure radiation therapy study . Uncontrolled malignant ascites . History brain metastasis , spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease screen CT MRI scan . Pregnant breastfeed woman . Uncontrolled hypertension Patients previously treat aflibercept History abdominal fistula , GI perforation , intraabdominal abscess within past 28 day . History hypersensitivity recombinant protein , irinotecan , fluoropyrimidine isovorin . Known dihydropyrimidine dehydrogenase deficiency . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>oxaliplatin</keyword>
	<keyword>5-FU</keyword>
	<keyword>Folinic Acid</keyword>
</DOC>